Trazodone Tablet Franchise in Ahmedabad

Antidepressant Tablet Supplier in Mumbai

Neuro Psychiatric Tablet Distributor in Delhi

Mental Health PCD Pharma Franchise in Bangalore

Trazodone Tablet Stockist in Hyderabad
Neuro Tablet Manufacturer & Exporter in Chandigarh

Home/Products /trazodone-hcl-ip-100-mg-tablet

Trazodin 150 Tablet

Composition : Trazodone (150mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Trazodin 150 Tablet contains Trazodone 150mg, a potent antidepressant used for the treatment of depressive disorders, anxiety-related depression, and sleep disturbances. It is widely prescribed for patients requiring effective neuropsychiatric management.

Trazodone works by modulating serotonin levels in the brain, helping improve mood, relieve anxiety, and promote restorative sleep. Its dual action makes it suitable for patients with depression and comorbid insomnia.

This tablet is commonly prescribed for major depressive disorder, chronic anxiety, and sleep disorders associated with mood disturbances. The 150mg strength allows flexible dosing in patients requiring moderate to high therapeutic levels under medical supervision.

For PCD pharma franchise partners, Trazodin 150 Tablet is a high-demand neuropsychiatric product, available at the best price for PCD pharma franchise. Its strong prescription demand, growing mental health awareness, and prescriber confidence make it an essential addition to any neuro or psychiatric medicine portfolio.

Read More

About the Product

Trazodin 150 Tablet contains Trazodone 150mg, a potent antidepressant used for the treatment of depressive disorders, anxiety-related depression, and sleep disturbances. It is widely prescribed for patients requiring effective neuropsychiatric management.

Trazodone works by modulating serotonin levels in the brain, helping improve mood, relieve anxiety, and promote restorative sleep. Its dual action makes it suitable for patients with depression and comorbid insomnia.

This tablet is commonly prescribed for major depressive disorder, chronic anxiety, and sleep disorders associated with mood disturbances. The 150mg strength allows flexible dosing in patients requiring moderate to high therapeutic levels under medical supervision.

For PCD pharma franchise partners, Trazodin 150 Tablet is a high-demand neuropsychiatric product, available at the best price for PCD pharma franchise. Its strong prescription demand, growing mental health awareness, and prescriber confidence make it an essential addition to any neuro or psychiatric medicine portfolio.

Common side effects may include drowsiness, dizziness, dry mouth, headache, nausea, and fatigue. Some patients may experience blurred vision or gastrointestinal discomfort. Most side effects are mild and reduce as the body adjusts to the medication.

Trazodin 100 Tablet is indicated for the treatment of major depressive disorder, anxiety associated with depression, and sleep disorders such as insomnia. It may also be prescribed to improve sleep quality in patients with mood disorders under medical supervision.

Trazodin 100 Tablet should be taken strictly as prescribed by a physician. Avoid alcohol and activities requiring mental alertness, such as driving, until the drug’s effects are known. Do not stop the medication abruptly without consulting a healthcare professional, as it may lead to withdrawal symptoms.

Store Trazodin 100 Tablet at room temperature in a cool, dry place away from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our Successful network today.

Quick Navigation

1500+ Products

Our Divisions

All Therapeutics

Disclaimer: Pharma Insights are based on operational standards as of March 2026. All territories are subject to availability and Revised Schedule M compliance.